Literature DB >> 30185124

Important Questions About the Impact of Medical Marijuana on People With Serious Mental Illness.

Mary F Brunette1, Jacob T Borodovsky1, Melissa Myers1, Alan J Budney1.   

Abstract

Many people are interested in using marijuana for therapeutic purposes as legalization expands across the country. The impact of marijuana depends upon the consumed potency and dose of its major psychoactive components, tetrahydrocannabinol and cannabidiol, which have very different psychiatric effects. This Open Forum discusses what is known about the impact of these marijuana constituents on people with serious mental illnesses, who may experience many adverse effects and more easily develop addiction with marijuana use. As use of medical marijuana increases, mental health clinicians can help prevent or address adverse effects by informing themselves and others about marijuana's effects and by coordinating with marijuana prescribers.

Entities:  

Keywords:  Mental illness & alcohol/drug abuse, Public health

Mesh:

Substances:

Year:  2018        PMID: 30185124      PMCID: PMC6436619          DOI: 10.1176/appi.ps.201800210

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  11 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing.

Authors:  Jeffrey C Raber; Sytze Elzinga; Charles Kaplan
Journal:  J Toxicol Sci       Date:  2015-12       Impact factor: 2.196

Review 3.  Cannabis-associated psychosis: Neural substrate and clinical impact.

Authors:  R M Murray; A Englund; A Abi-Dargham; D A Lewis; M Di Forti; C Davies; M Sherif; P McGuire; D C D'Souza
Journal:  Neuropharmacology       Date:  2017-06-17       Impact factor: 5.250

4.  Changes in Cannabis Potency Over the Last 2 Decades (1995-2014): Analysis of Current Data in the United States.

Authors:  Mahmoud A ElSohly; Zlatko Mehmedic; Susan Foster; Chandrani Gon; Suman Chandra; James C Church
Journal:  Biol Psychiatry       Date:  2016-01-19       Impact factor: 13.382

5.  Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products.

Authors:  Ryan Vandrey; Jeffrey C Raber; Mark E Raber; Brad Douglass; Cameron Miller; Marcel O Bonn-Miller
Journal:  JAMA       Date:  2015 Jun 23-30       Impact factor: 56.272

Review 6.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

7.  Labeling Accuracy of Cannabidiol Extracts Sold Online.

Authors:  Marcel O Bonn-Miller; Mallory J E Loflin; Brian F Thomas; Jahan P Marcu; Travis Hyke; Ryan Vandrey
Journal:  JAMA       Date:  2017-11-07       Impact factor: 56.272

Review 8.  Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review.

Authors:  Nora D Volkow; James M Swanson; A Eden Evins; Lynn E DeLisi; Madeline H Meier; Raul Gonzalez; Michael A P Bloomfield; H Valerie Curran; Ruben Baler
Journal:  JAMA Psychiatry       Date:  2016-03       Impact factor: 21.596

9.  The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products.

Authors:  Nick Jikomes; Michael Zoorob
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

10.  Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.

Authors:  Philip McGuire; Philip Robson; Wieslaw Jerzy Cubala; Daniel Vasile; Paul Dugald Morrison; Rachel Barron; Adam Taylor; Stephen Wright
Journal:  Am J Psychiatry       Date:  2017-12-15       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.